title: [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis].
abstract: Sulphasalazine (SSZ) is now recognised to be a useful agent in the management of rheumatoid arthritis (RA). We studied SSZ toxicity (2 g/die) and duration of therapy in 102 patients with RA. Adverse events occurred in 25.4% of all patients. In all patients the reactions subsided on either discontinuation of the drug or decrease of the dose. Gastrointestinal was the most common. At 5 years of follow-up the percentage of patients treated with SSZ still on drug was 29%, the inefficacy was 40% of the total drop-out.
authors.affiliation: Clinica Reumatologica, Università degli Studi di Ancona.
authors.forename: A
authors.initials: A
authors.lastname: Mundo
authors.forename: V
authors.initials: V
authors.lastname: Pedone
authors.forename: G
authors.initials: G
authors.lastname: Lamanna
authors.forename: C
authors.initials: C
authors.lastname: Cervini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D012460:Sulfasalazine